Search research articles
Contact Us
Filters
Showing results (161-170 of 180) with videos related to
Page
of 18
Sort By:
European Journal of Medicinal Chemistry
|
October 15, 2022
Development of [1,2]oxazoloisoindoles tubulin polymerization inhibitors: Further chemical modifications and potential therapeutic effects against lymphomas
Marilia Barreca, Virginia Spanò, Roberta Rocca, et al.
Haematologica
|
June 19, 2025
Novel PI3kδ inhibitor roginolisib synergizes with venetoclax in hematologic malignancies
Binu Kandathilparambil Sasi, Chiara Tarantelli, Stephen Martindale, et al.
Physical Review Letters
|
September 28, 2010
Double core-hole production in N2: beating the Auger clock
L Fang, M Hoener, O Gessner, et al.
Biorxiv : the Preprint Server for Biology
|
November 28, 2023
PI3Kδ activation, IL6 over-expression, and CD37 loss cause resistance to the targeting of CD37-positive lymphomas with the antibody-drug conjugate naratuximab emtansine
Alberto J Arribas, Eugenio Gaudio, Sara Napoli, et al.
Haematologica
|
December 15, 2018
New molecular and therapeutic insights into canine diffuse large B-cell lymphoma elucidates the role of the dog as a model for human disease
Luca Aresu, Serena Ferraresso, Laura Marconato, et al.
Blood Advances
|
October 7, 2024
PI3Kδ activation, IL-6 overexpression, and CD37 loss cause resistance to naratuximab emtansine in lymphomas
Alberto J Arribas, Sara Napoli, Eugenio Gaudio, et al.
Haematologica
|
May 9, 2024
Targeting CD19-positive lymphomas with the antibodydrug conjugate loncastuximab tesirine: preclinical evidence of activity as a single agent and in combination therapy
Chiara Tarantelli, David Wald, Nicolas Munz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 12, 2019
The ETS Inhibitors YK-4-279 and TK-216 Are Novel Antilymphoma Agents
Filippo Spriano, Elaine Yee Lin Chung, Eugenio Gaudio, et al.
Molecular Cancer Therapeutics
|
December 5, 2023
ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms
Alberto J Arribas, Sara Napoli, Luciano Cascione, et al.
Biorxiv : the Preprint Server for Biology
|
January 30, 2023
ERBB4-mediated signaling is a mediator of resistance to BTK and PI3K inhibitors in B cell lymphoid neoplasms
Alberto J Arribas, Sara Napoli, Luciano Cascione, et al.
Page
of 18
Search research articles
Search
Showing results (161-170 of 180) with videos related to
Sort By:
Page
of 18
European Journal of Medicinal Chemistry
|
October 15, 2022
Development of [1,2]oxazoloisoindoles tubulin polymerization inhibitors: Further chemical modifications and potential therapeutic effects against lymphomas
Marilia Barreca, Virginia Spanò, Roberta Rocca, et al.
Haematologica
|
June 19, 2025
Novel PI3kδ inhibitor roginolisib synergizes with venetoclax in hematologic malignancies
Binu Kandathilparambil Sasi, Chiara Tarantelli, Stephen Martindale, et al.
Physical Review Letters
|
September 28, 2010
Double core-hole production in N2: beating the Auger clock
L Fang, M Hoener, O Gessner, et al.
Biorxiv : the Preprint Server for Biology
|
November 28, 2023
PI3Kδ activation, IL6 over-expression, and CD37 loss cause resistance to the targeting of CD37-positive lymphomas with the antibody-drug conjugate naratuximab emtansine
Alberto J Arribas, Eugenio Gaudio, Sara Napoli, et al.
Haematologica
|
December 15, 2018
New molecular and therapeutic insights into canine diffuse large B-cell lymphoma elucidates the role of the dog as a model for human disease
Luca Aresu, Serena Ferraresso, Laura Marconato, et al.
Blood Advances
|
October 7, 2024
PI3Kδ activation, IL-6 overexpression, and CD37 loss cause resistance to naratuximab emtansine in lymphomas
Alberto J Arribas, Sara Napoli, Eugenio Gaudio, et al.
Haematologica
|
May 9, 2024
Targeting CD19-positive lymphomas with the antibodydrug conjugate loncastuximab tesirine: preclinical evidence of activity as a single agent and in combination therapy
Chiara Tarantelli, David Wald, Nicolas Munz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 12, 2019
The ETS Inhibitors YK-4-279 and TK-216 Are Novel Antilymphoma Agents
Filippo Spriano, Elaine Yee Lin Chung, Eugenio Gaudio, et al.
Molecular Cancer Therapeutics
|
December 5, 2023
ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms
Alberto J Arribas, Sara Napoli, Luciano Cascione, et al.
Biorxiv : the Preprint Server for Biology
|
January 30, 2023
ERBB4-mediated signaling is a mediator of resistance to BTK and PI3K inhibitors in B cell lymphoid neoplasms
Alberto J Arribas, Sara Napoli, Luciano Cascione, et al.
Page
of 18